Advancing candidates designed to address resistance mechanisms in multiple cancers

Pipeline Schematic. Oric-101 Glucocorticoid receptor antagonist for prostate cancer in Phase 1B Oric-101 plus Xtandi.
Oric-101 glucocorticoid recepotr antagonist for solid tummors in phase 1b Oric-101 plus Abraxane.
Oric-533 CD73 inhibitor for multiple myeloma in Phase 1b Oric-533 single agent.
Oric-114 EGFR/HER2 exon 20 inhibitor for NSCLC, Breast & Tumor agnostic in Phase 1B ORIC-114 single agent.
ORIC-944 PRC2 inhibitor for prostate cancer in Phase 1b Oric-944 single agent.
Multiple programs targeting resistance mechanisms for solid tumors in lead optimization.

Our portfolio of novel agents targets multiple resistance mechanisms by leveraging our specialized expertise in the following areas:

Precision Oncology
Using biomarkers and targeted therapeutics to identify the right drugs for the right patients
Key Tumor Dependencies
Using our resistance platform to target cancer-specific vulnerabilities
Hormone-Dependent Cancers
Using our expertise in hormonally dependent cancers to prevent relapse or reverse resistance

Scanning Electron Microscopy of dividing cancer cell with cancer cells floating in background


GR is a nuclear hormone receptor that mediates responses to glucocorticoid hormones involved in regulating a range of cellular functions, such as metabolism, cell growth and differentiation. Roughly in parallel, two distinct and uncorrelated mechanisms of GR-mediated resistance to anti-cancer therapies began to be studied by oncology experts. The original hypothesis for our lead program targeting GR was borne out of work conducted in the laboratory of Dr. Sawyers at MSKCC in search of explanatory factors underlying resistance to anti-androgen prostate cancer therapies, including Xtandi® and Erleada®. His work demonstrated that GR signaling is a bypass mechanism to anti-androgen therapy, with GR taking over for AR signaling, and that increased expression of GR in prostate cancer is correlated with resistance to Xtandi. Similarly, GR has also been studied for its potential role in mediating resistance to chemotherapy, though in this case, the mechanism appears to be related to GR’s role in imparting a “pro-survival” phenotype on the tumor via certain biological processes like epithelial-to-mesenchymal (EMT) transition and anti-apoptosis. We and others have shown that GR is overexpressed across over 20 advanced solid tumors including prostate, pancreatic, triple negative breast (TNBC) and ovarian cancers, and that GR overexpression is associated with worse survival outcomes for patients treated with anti-androgen therapies in prostate cancer and chemotherapy in other solid tumors.

Our lead product candidate, ORIC-101, is a potent and selective small molecule GR antagonist designed to inhibit GR transcriptional activity and block pro-survival signals downstream of its activation that confer resistance to anti-androgen therapies and chemotherapies. Since its initial discovery at ORIC, we have rapidly advanced ORIC-101 through preclinical studies that have informed the design of a robust clinical development plan. Following the successful completion of two Phase 1a trials in over 50 healthy volunteers, we initiated in 2019 two separate Phase 1b trials of ORIC-101 in combination with: (1) enzalutamide in metastatic prostate cancer and (2) nab-paclitaxel in advanced or metastatic solid tumors. These trials are intended to establish safety, pharmacokinetics, pharmacodynamics, preliminary anti-tumor activity and a recommended Phase 2 dose of ORIC-101 in combination with each of these therapeutics.

More information about our clinical trials is available here.


Many cancers usurp the anti-inflammatory adenosine pathway to avoid detection by the immune system, thereby reducing the effectiveness of certain chemotherapy- and immunotherapy-based treatments. Accumulation of adenosine in the tumor microenvironment is implicated in local immune suppression that leads to tumor growth. CD73 is an enzyme that controls the rate at which extracellular adenosine is produced and its overexpression is associated with poor prognosis in several cancers, including TNBC, NSCLC, melanoma and prostate, among others. Our second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73 that has demonstrated more potent adenosine inhibition in vitro compared to an antibody-based approach.

Adenosine Pathway Overview
Schematic of the adenosine pathway
CD73 Background
  • Overexpressed across cancer
    types driving local elevation
    of adenosine
  • Expression is correlated with
    poor prognosis
  • Mediates immunosuppression
    and chemoresistance via
    adenosine production
  • Upregulated in response to
    PD-1/L1 and CTLA-4 inhibition
Therapeutic Hypothesis
  • CD73 inhibition may enhance activity of chemotherapy and immunotherapy
  • Small molecule approach is mechanistically distinct from antibodies and may
    differentiate in safety profile, dosing regimen and tumor penetration


The ErbB receptor tyrosine kinase family is involved in key cellular functions, including cell growth and survival. Epidermal growth factor receptor (EGFR, or ErbB1) and human epidermal growth factor receptor 2 (HER2, or ErbB2) exon 20 insertion mutations are observed across multiple solid tumors, including NSCLC, breast, gastrointestinal, bladder and other cancers. EGFR exon 20 insertion mutations are observed in approximately 2% of all patients with NSCLC and have a worse prognosis than patients with NSCLC driven by other EGFR mutations. HER2 exon 20 insertion mutations are observed in approximately 1.5% of all patients with NSCLC. Approximately one-third of patients with exon 20 insertion mutations may develop brain metastases, which contributes to poor prognosis.

ORIC-114 is a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations. ORIC-114 has demonstrated greater brain exposure in preclinical studies compared to other compounds being developed against exon 20 mutations and demonstrates strong anti-tumor activity in an EGFR-driven intracranial lung cancer model.


The dysregulation of Polycomb Repressive Complex 2 (PRC2) methyltransferase activity can lead to tumorigenesis in a wide range of cancers including prostate cancer, breast cancer, and hematological malignancies. EED is a core component of PRC2 and allosteric inhibition of EED impacts the assembly, stabilization, and activation of PRC2. Several companies are developing EZH2 inhibitors; however, the pharmacologic properties of these compounds result in high doses that achieve only partial target inhibition in the clinic. Additionally, preclinical studies suggest drug resistance to EZH2 inhibitors may develop via EZH1 bypass compensation or acquired mutations in EZH2. ORIC-944 is a potent and selective allosteric inhibitor of PRC2/EED and is efficacious in enzalutamide-resistance prostate cancer models in preclinical studies.

PRC2 Function
Schematic of PRC2 function dysregulation leading to tumorigenesis
PRC2 Background
  • Two druggable subunits:
    – EED: responsible for histone binding; target of ORIC-944

    – EZH2: responsible for histone methylation; target of first-generation inhibitors

  • Dysregulation of PRC2 linked to several cancers
    – Decreased expression of target genes associated with poor prognosis in prostate cancer
  • First-generation inhibitors, designed to inhibit EZH2, have demonstrated promising clinical activity and chemoresistance via
    – Approved for epithelioid sarcoma and follicular lymphoma
    – Limited progress made for treatment of prostate cancer
PRC2 is a validated oncogenic target across several cancers with promising
therapeutic potential in prostate cancer, among other indications

Cancer cell surrounded by many smaller cancer cells on orange background


In addition to our product candidates, we are leveraging our resistance platform in pursuit of multiple discovery research programs that focus on our expertise within hormone-dependent cancers, precision oncology and key tumor dependencies. These programs highlight our medicinal chemistry and structure-based design expertise, thus for the most part utilize a small molecule therapeutic approach to target oncogenic drivers in solid tumors like prostate, breast and lung cancer that relapse with innate, acquired or bypass resistance. Our most advanced discovery research programs are currently in lead identification and undergoing in vitro studies.